NRx Pharma sube por la aprobación de la FDA para inyección genérica de ketamina

Resumen del corpus

NRx Pharmaceuticals, Inc. (NRXP) saw a significant increase in its stock price after the FDA approved its generic injection of ketamine. This approval could alleviate supply restrictions for pain and anesthesia therapies in the United States. The approval is for a new abbreviated version of the drug, which is a positive development for the market.